None
Conditions
Interventions
Norepinephrine Group:Norepinephrine was prepared at a concentration of 8 µg/mL. Starting from the beginning of maintenance anesthesia, patients in the norepinephrine group received an initial infusion
Phenylephrine Group:The stock solution of phenylephrine (100 µg/mL) was drawn up. For patients in the phenylephrine (PE) group, phenylephrine was infused at an initial rate of 0.1–0.2 µg/kg/min starti
Sponsors
Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Elective thoracoscopic radical resection for lung cancer(including lobectomy, segmentectomy, and wedge resection); 2.Age 18–70 years; 3. ASA physical status Grade I–III; 4.Voluntary participation and acceptance of intraoperative intervention.
Exclusion criteria
Exclusion criteria: 1.The patient refused to participate in this study voluntarily. 2.Patients with abnormal spinal anatomical structure, space-occupying lesions, or pathological changes of the spine. 3.Patients with tumors, bleeding, or infection at or around the puncture site for paravertebral block. 4.Severe dysfunction of the heart, brain, lung, liver, or kidney. 5.Patients with a clinically assessed cardiac function of less than 3 metabolic equivalents (METs), and with angina pectoris and/or precordial discomfort (chest tightness or pain during general physical activity) within 3 months prior to surgery. 6.Patients with preoperative atrial fibrillation, non-sinus rhythm, or those taking antiarrhythmic drugs, anticoagulants, or antiplatelet agents preoperatively. 7.Severe coagulation dysfunction. 8.Patients with hypersensitivity to the drugs used in this study (ropivacaine, norepinephrine, phenylephrine, etc.). 9.Body mass index (BMI) > 30 kg/m^2. 10.Patients with severe mental disorders, inability to communicate, or inability to complete scales independently. 11.Diabetes mellitus complicated with peripheral neuropathy. 12.Poorly controlled central nervous system diseases. 13.Patients with concomitant hematological or immune system diseases (long-term use of immunosuppressants and/or corticosteroids). 14.Surgery involving bilateral thoracic cavities.15.Pregnant or lactating patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fibrin(ogen) degradation products(FDP);D-dimer level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neutrophil-Lymphocyte Ratio(NLR);Platelet-Lymphocyte Ratio( PLR);Blood gas analysis;Perioperative thromboembolism-related complications;Other complications;Volume of bloody drainage from thoracic drainage tube within 24 hours postoperatively; | — |
Countries
China
Contacts
Public ContactXiaoyan Zhu
Xiangya Hospital of Central South University
Outcome results
None listed